- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2202
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
In silico repurposing of antipsychotic drugs for Alzheimer’s disease ; volume:18 ; number:1 ; day:27 ; month:10 ; year:2017 ; pages:1-16 ; date:12.2017
BMC neuroscience ; 18, Heft 1 (27.10.2017), 1-16, 12.2017
- Schlagwort
-
Arzneimittelentwicklung
Arzneimitteldesign
- Urheber
-
Kumar, Shivani
- Beteiligte Personen und Organisationen
-
Chowdhury, Suman
Kumar, Suresh
SpringerLink (Online service)
- DOI
-
10.1186/s12868-017-0394-8
- URN
-
urn:nbn:de:1111-2017122010446
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kumar, Shivani
- Chowdhury, Suman
- Kumar, Suresh
- SpringerLink (Online service)
Ähnliche Objekte (12)
Single-cell-led drug repurposing for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Alzheimer’s Disease Drug Development Pipeline 2020
Single-cell-led drug repurposing for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Alzheimer’s Disease Drug Development Pipeline 2020
Single-cell-led drug repurposing for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice